AU5319499A - Fatty acids to minimize cancer therapy side effects - Google Patents

Fatty acids to minimize cancer therapy side effects

Info

Publication number
AU5319499A
AU5319499A AU53194/99A AU5319499A AU5319499A AU 5319499 A AU5319499 A AU 5319499A AU 53194/99 A AU53194/99 A AU 53194/99A AU 5319499 A AU5319499 A AU 5319499A AU 5319499 A AU5319499 A AU 5319499A
Authority
AU
Australia
Prior art keywords
fatty acids
side effects
cancer therapy
therapy side
minimize
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU53194/99A
Inventor
Ivan L. Cameron
W. Elaine Hardman
Mary Pat Moyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INCELL Corp LLC
Original Assignee
INCELL Corp LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INCELL Corp LLC filed Critical INCELL Corp LLC
Publication of AU5319499A publication Critical patent/AU5319499A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pediatric Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU53194/99A 1999-07-22 1999-07-22 Fatty acids to minimize cancer therapy side effects Abandoned AU5319499A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/016666 WO2001006983A2 (en) 1999-07-22 1999-07-22 Fatty acids to minimize cancer therapy side effects

Publications (1)

Publication Number Publication Date
AU5319499A true AU5319499A (en) 2001-02-13

Family

ID=22273263

Family Applications (1)

Application Number Title Priority Date Filing Date
AU53194/99A Abandoned AU5319499A (en) 1999-07-22 1999-07-22 Fatty acids to minimize cancer therapy side effects

Country Status (2)

Country Link
AU (1) AU5319499A (en)
WO (1) WO2001006983A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ555163A (en) * 2007-05-14 2010-05-28 Fonterra Co Operative Group Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
DK2180787T3 (en) 2007-08-01 2014-02-03 Univ Pittsburgh NITROOLIC ACID MODULATION OF TYPE II DIABETES
CA2729053A1 (en) 2008-05-01 2009-11-05 Bruce A. Freeman Vinyl substituted fatty acids
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
CN102099024B (en) * 2008-06-19 2015-11-25 犹他大学研究基金会 The purposes of nitrated lipid in the treatment of the side effect of toxicity medical therapies
EP3045167A1 (en) 2009-07-31 2016-07-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Keto fatty acids as anti-inflammatory agents
WO2011041639A2 (en) 2009-10-02 2011-04-07 Miller Raymond A Heteroatom containing substituted fatty acids
AU2010310515B2 (en) * 2009-10-22 2016-01-07 University Of Southern California Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment
WO2012141575A1 (en) * 2011-04-14 2012-10-18 N.V.Nutricia Combination of epa, dpa and/or dha with a chemotherapeutic agent
EP2744491B1 (en) 2011-08-19 2020-07-29 The University of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
SI2800563T1 (en) 2012-01-06 2018-11-30 Omthera Pharmaceuticals Inc. Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
EP2846779A4 (en) 2012-05-07 2015-12-16 Omthera Pharmaceuticals Inc Compositions of statins and omega-3 fatty acids
AU2016289856B2 (en) 2015-07-07 2020-11-26 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
EP3355879A4 (en) 2015-10-02 2019-05-22 Complexa, Inc. Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
TW201827047A (en) 2016-12-23 2018-08-01 挪威商普諾瓦生物製藥挪威公司 Omega-3 fatty acid composition for preventing and/or treating cachexia
US10905724B2 (en) * 2017-06-13 2021-02-02 Houn Simon Hsia Compositions and methods for enhancing hyperthermia therapy
SI3801526T1 (en) 2018-05-25 2024-05-31 Cardurion Pharmaceuticals, Inc. Monohydrate and crystalline forms of 6-((3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-tetrahydropyran-4-yl- 7h-imid azo (1,5- a) pyrazin-8-one

Also Published As

Publication number Publication date
WO2001006983A2 (en) 2001-02-01

Similar Documents

Publication Publication Date Title
AU5319499A (en) Fatty acids to minimize cancer therapy side effects
EP1212327B8 (en) Pyrazolopyrimidines as therapeutic agents
AU3783599A (en) Non-invasive methods to detect prostate cancer
NZ298712A (en) Fatty acid acyl group conjugates as therapeutic compounds
AU3843200A (en) Conjugated fatty acid esters
AUPQ071299A0 (en) Vitamin directed dual targeting therapy
AU6078500A (en) Combination therapy for conditions leading to bone loss
AU7882900A (en) Hydrotherapy bed
AU6208100A (en) Cancer treatment using angiopoietins targeted to aminophospholipids
AU7597000A (en) Imaging of drug accumulation as a guide to antitumor therapy
EP1242071A4 (en) Use of parthenolide to inhibit cancer
AU2634101A (en) Therapeutic preparations of highly unsaturated fatty acids
AU3082401A (en) Therapy of psoriasis
AU2451500A (en) Therapeutic agents
AU8021000A (en) Method for the direct esterification of sorbitol with fatty acids
AUPQ480399A0 (en) Unsaturated fatty acids and their uses in therapy
AU7089800A (en) 29 human cancer associated proteins
AU4443599A (en) Therapeutic bed
AU2205801A (en) Novel compounds of unsaturated fatty acids
SG93225A1 (en) Higher unsaturated fatty acid composition
AU5552400A (en) Treatment of cancer
AUPQ367699A0 (en) Treatment of cancer
AU5973600A (en) Therapeutic agents
AU7920198A (en) Intratumoral administration of triphenylethylenes for the treatment of cancer
AU8139498A (en) Preparation for topical application to the male sexual organ

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase